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Abstract
Objective:  Intussusception  surveillance  was  initiated  after  the  nationwide  introduction  of  live
attenuated  monovalent  rotavirus  vaccine  (RV1).  The  objective  is  to  assess  the  epidemiology  of
intussusception  and  compare  the  number  of  cases  before  and  after  the  introduction  of  rotavirus
vaccine.
Methods: Cases  of  intussusception  occurring  between  March  2006  and  January  2008  were  iden-
tiﬁed through  a  prospective  enhanced  passive  surveillance  system  established  in  sentinel  state
hospitals.  Retrospective  review  of  medical  records  was  used  to  identify  cases,  which  occurred
in sentinel  hospitals  between  January  2001  and  February  2006.
Results: From  2001  to  2008,  331  intussusception  cases  were  identiﬁed,  59.5%  were  male,  with
peak incidence  among  those  18--24  weeks  of  age.  Overall  <10%  of  cases  were  among  infants  6--14
weeks of  age  (when  the  ﬁrst  dose  of  RV1  is  administered).  The  most  frequently  observed  signs
or symptoms  of  intussusception  included  vomiting  (89.4%),  bloody  stool  (75.5%),  and  abdominal
distention  (71.8%).  A  majority  (92.1%)  of  the  case-patients  required  surgery  for  treatment;
31.8% of  those  who  underwent  surgery  required  bowel  resection,  and  13  (3.9%)  died.  Among
the 21  hospitals  that  reported  cases  throughout  the  entire  surveillance  period  (2001--2008),  the
number of  intussusception  events  during  2007  (n  =  26)  and  2008  (n  =  19)  was  not  greater  than
the average  annual  number  (n  =  31,  range  24--42)  during  baseline  years  2001--2005.
 Please cite this article as: Fernandes EG, Leshem E, Patel M, Flannery B, Pellini AC, Veras MA, et al. Hospital-based surveillance of
intussusception among infants. J Pediatr (Rio J). 2016;92:181--7.
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Conclusions:  Although  this  analysis  did  not  identify  an  increase  in  intussusception  cases  during
the two  years  after  RV1  introduction,  these  results  support  the  need  for  special  epidemiologic
methods  to  assess  the  potential  link  between  rotavirus  vaccine  and  this  very  rare  adverse  event.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Vigilância  hospitalar  de  intussuscepc¸ão entre  neonatos
Resumo
Objetivo:  A  vigilância  da  intussuscepc¸ão  foi  iniciada  após  a  introduc¸ão  da  vacina  monovalente
viva atenuada  contra  rotavírus  (RV1)  em  todo  o  país.  O  objetivo  é  avaliar  a  epidemiologia  da
intussuscepc¸ão e  comparar  a  quantidade  de  casos  antes  e  depois  da  introduc¸ão  da  vacina  contra
rotavírus.
Métodos: Os  casos  de  intussuscepc¸ão  entre  marc¸o  de  2006  e  janeiro  de  2008  foram  identiﬁcados
por meio  de  um  sistema  de  vigilância  passivo  prospectivo  aprimorado  estabelecido  em  hospitais-
sentinela estaduais.  A  análise  retrospectiva  de  prontuários  médicos  foi  utilizada  para  identiﬁcar
os casos  que  ocorreram  em  hospitais-sentinela  entre  janeiro  de  2001  e  fevereiro  de  2006.
Resultados:  De  2001-2008,  identiﬁcamos  331  casos  de  intussuscepc¸ão,  59,5%  dos  quais  ocor-
reram em  pacientes  do  sexo  masculino,  com  pico  de  incidência  entre  aqueles  com  18-24  semanas
de idade.  Em  geral,  <  10%  dos  casos  ocorreram  entre  neonatos  com  6-14  semanas  de  idade
(quando a  1a dose  de  RV1  é  administrada).  Os  sinais  ou  sintomas  de  intussuscepc¸ão  observados
com mais  frequência  incluíam  vômito  (89,4%),  fezes  com  sangue  (75,5%)  e  distensão  abdominal
(71,8%).  A  maioria  (92,1%)  dos  pacientes  precisou  de  cirurgia  para  o  tratamento;  31,8%  dos
que se  submeteram  à  cirurgia  precisaram  de  ressecc¸ão  intestinal,  e  13  (3,9%)  vieram  a  óbito.
Entre os  21  hospitais  que  relataram  casos  durante  todo  o  período  de  vigilância  (2001-2008),
a quantidade  de  casos  de  intussuscepc¸ão  em  2007  (n  =  26)  e  2008  (n  =  19)  não  foi  maior  que  a
quantidade  média  anual  (31,  faixa  de  24-42)  durante  os  anos-base  de  2001-2005.
Conclusões:  Embora  esta  análise  não  tenha  identiﬁcado  um  aumento  nos  casos  de
intussuscepc¸ão nos  dois  anos  após  a  introduc¸ão  da  RV1,  esses  resultados  justiﬁcam  a  neces-
sidade de  métodos  epidemiológicos  especiais  para  avaliar  a  possível  associac¸ão  entre  a  vacina
contra rotavírus  e  esse  evento  adverso  muito  raro.
© 2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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otavirus  is  a  leading  cause  of  severe  diarrhea,  accounting
or  ∼453,000  deaths  annually  among  children  <5  years  of  age
orldwide.1 The  World  Health  Organization  (WHO)  has  rec-
mmended  global  introduction  of  one  of  the  two  licensed
otavirus  vaccines  [RotaTeq  or  RV5  (Merck®,  PA,  USA)  and
otarix  or  RV1  (Rotarix®,  GlaxoSmithKline  Biologicals,  Rix-
nsart,  Belgium)]  in  national  immunization  programs  for
reventing  severe  rotavirus  disease.2 In  March  2006,  the
razilian  Ministry  of  Health  introduced  RV1,  a  live  attenu-
ted  monovalent  vaccine  derived  from  human  G1P[8]  strain,
imultaneously  in  all  27  states,  through  its  National  Immu-
ization  Program  (Programa  Nacional  de  Imunizac¸ão  [PNI]).
A  key  issue  for  rotavirus  vaccine  immunization  pro-
rams  is  the  need  for  safety  monitoring  with  regard  to
ntussusception,  a  form  of  intestinal  obstruction  occurring
t  a  background  rate  of  approximately  50  per  100,000
nfants.3 An  earlier  rotavirus  vaccine  (Rotashield,  Wyeth
accines,  PA,  USA)  based  on  a  different  (rhesus)  strain  than
he  current  WHO  recommended  vaccines  was  found  to  be
ssociated  with  an  increased  risk  of  intussusception,  with
he  vaccine  causing  roughly  ten  excess  cases  per  100,000
d
t
iaccinated  infants.4 Large  clinical  trials  have  not  detected  a
isk  of  intussusception  associated  with  either  currently  used
accines5,6;  however,  post-licensure  surveillance  in  Mexico
nd  Australia  has  observed  a  small  risk  of  intussusception
fter  the  initial  dose.7,8 In  Mexico,  an  association  was  found
etween  RV1  and  intussusception,  with  the  vaccine  caus-
ng  one  to  four  excess  cases  of  intussusception  per  100,000
accinated  infants.8,9 In  Australia,  a  possible  temporal  clus-
ering  of  intussusception  episodes  was  noted  during  the
even  days  after  the  initial  dose  of  both  RV1  and  RV5,  though
here  was  no  increase  in  overall  risk  at  12  months  of  age.7 In
razil,  no  increased  risk  was  identiﬁed  after  the  ﬁrst  dose,
ut  a  potential  small  risk  was  identiﬁed  after  the  second
ose  of  RV1  (excess  of  1.5  cases  per  100,000  vaccinated
nfants).9 No  deﬁnite  increased  risk  of  intussusception  has
een  identiﬁed  after  use  of  RV5  in  the  United  States,  but
n  excess  risk  less  than  one  in  65,000  vaccinated  infants
as  not  been  excluded.10 Marked  declines  in  severe  and
atal  diarrhea  were  demonstrated  in  early  adopter  countries
fter  the  introduction  of  rotavirus  vaccine.11 Because  the
ocumented  beneﬁts  of  vaccination  have  far  outweighed
he  low-level  risk  of  intussusception  observed  in  some  sett-
ngs,  regulatory  agencies  have  continued  to  recommend
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Intussusception surveillance in São Paulo State/Brazil
Hospital based surveillance
n=331 cases
 21 Hospitals
Notifications
from 2001 to 2008 
3 Hospitals
Notifications from
 2001 to 2005 
34 Hospitals
Notifications from
 2006 to 2008
Figure  1  Intussusceptions  surveillance  among  infants  aged
<12 months  based  on  58  hospitals  in  São  Paulo  State,  Brazil,
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ted  by  calendar  year,  according  to  four  age  groups:  <6Hospital-based  surveillance  of  intussusception  
rotavirus  vaccination  for  all  children  worldwide.2 Ongoing
post-licensure  monitoring  of  the  safety  and  effectiveness  of
rotavirus  vaccines  is  crucial  for  assessing  the  risk/beneﬁt
proﬁle  of  rotavirus  vaccines.
This  study’s  objective  was  to  monitor  and  characterizes
the  intussusception  events  in  a  subset  of  participating  hos-
pitals  and  compares  the  number  of  intussusceptions  cases
before  and  after  the  introduction  of  rotavirus  vaccine.
Materials and methods
Intussusception  case  deﬁnition
Intussusception  case-patients  were  included  if  registered  as
State  of  São  Paulo  residents,  aged  less  than  1  year,  and
diagnosed  with  deﬁnite  intussusception  based  on  Level  I  of
diagnostic  certainty  as  deﬁned  by  the  Brighton  Collabora-
tion  Intussusception  Working  Group  criteria.12 Diagnosis  of
intussusception  is  classiﬁed  as  Level  1  if  conﬁrmed  by  air  or
liquid  contrast  enema,  ultrasound  (with  conﬁrmed  reduc-
tion  on  subsequent  ultrasound  or  enema),  or  at  surgery  or
autopsy.
Setting  and  data  sources
São  Paulo  is  a  highly  industrialized  Brazilian  state.  It
is  also  the  most  populous:  over  41  million  people  live
there  (41,579,695  in  2011).  The  newborn  cohort  has  been
decreasing  in  recent  years.  In  2001,  686,533  children  were
born  in  São  Paulo,  while  605,558  were  born  in  2008.13 Two-
dose  rotavirus  vaccine  coverage  among  children  <1  year  of
age  reached  85.1%  in  2007  and  86.3%  in  2008.14 In  São  Paulo
state,  there  are  9549  clinical  pediatric  beds  and  1048  pedi-
atric  surgery  beds  distributed  across  893  public  and  private
hospitals.
Data  on  intussusception  were  obtained  from  58  hospi-
tals  in  São  Paulo  state  from  2001  through  2008.  These
sentinel  hospitals  were  selected  from  those  with  pediatric
surgery  services  that  served  as  the  primary  referral  hos-
pital  for  intestinal  obstruction  in  each  metropolitan  area
or  groups  of  municipalities  (Fig.  1).  Not  all  of  these  hos-
pitals  conducted  surveillance  during  the  entire  2001--2008
study  period.  Thus,  for  comparison  of  the  pre-vaccine  and
post-vaccine  periods,  data  was  only  used  from  21  of  the
58  hospitals  that  conducted  intussusception  surveillance
for  the  entire  2001--2008  period.  These  hospitals  contain
10.2%  of  the  clinical  pediatrics  beds  and  12.7%  of  the  pedi-
atric  surgery  beds  of  São  Paulo  state,  but  accounted  for
approximately  30%  of  the  discharge  diagnoses  of  intesti-
nal  obstruction  identiﬁed  among  children  younger  than  1
year  of  age  admitted  in  public  hospitals  in  São  Paulo  during
2001--2005.
Two  approaches  were  used  to  ascertain  intussusception
cases.  To  establish  a  pre-vaccine  baseline,  intussusception
cases  hospitalized  between  January  2001  and  February  2006
were  identiﬁed  at  each  sentinel  hospital  through  retro-
spective  review  of  discharge  diagnoses  coded  as  intestinal
obstruction  (K56),  according  to  the  International  Classiﬁ-
cation  of  Diseases,  10th  edition  (ICD-10),  and  diagnoses
of  intussusception  in  radiology  or  surgical  log-books.  The
search  was  conducted  during  2006  and  data  were  abstracted
w
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U001--2008.
rom  medical  records  using  standardized  forms.  Cases
ccurring  between  March  2006  and  December  2008  were
dentiﬁed  through  a  prospective  surveillance  system  that
as  established  in  sentinel  private  and  public  state  hos-
itals.  Medical  and  surgical  staff  at  sentinel  hospitals
articipated  in  an  initial  training  in  identifying  intussus-
eption  cases  using  the  validated  Brighton  Collaboration
evel  I  case  deﬁnition.  Hospital  staff,  particularly  pedi-
tric  surgeons,  were  asked  to  report  cases  electronically
sing  a  standard  data  collection  form.  Periodic  visits  and
alls  were  made  to  the  hospital  to  encourage  reporting  and
o  address  concerns.  Periodic  review  of  surgical  and  radi-
logy  logs  was  conducted  to  ensure  the  thoroughness  of
eporting.
tatistical  analysis
he  demographic  and  clinical  characteristics  of  case-
atients  from  all  hospitals  were  summarized  using  descrip-
ive  statistics.  To  examine  potential  seasonal  variation  and
ge  distribution  of  intussusception  cases,  the  number  of
ntussusception  hospitalizations  in  São  Paulo  was  plotted  by
ear  and  week  of  age.  For  this  analysis,  cases  from  all  58
urveillance  hospitals  were  used.
It  was  also  of  interest  to  monitor  changes  in  number
f  intussusception  cases  before  and  after  the  introduc-
ion  of  vaccine.  Thus,  the  number  of  intussusception  cases
er  year  was  plotted  for  those  21  hospitals  that  con-
ucted  surveillance  during  the  entire  2001--2008  period.
ecause  rotavirus  vaccine  coverage  among  infants  was
igh  after  2006,14 this  study  compared  the  number  of
ntussusception  events  during  2007  and  2008  with  the  aver-
ge  annual  number  of  cases  during  the  baseline  years
001--2005,  considering  2006  as  a  transition  year  when
otavirus  vaccine  was  being  introduced.  The  number  of
ntussusception  cases  from  these  21  hospitals  was  also  plot-eeks,  6--14  weeks,  15--24  weeks,  and  25--52  weeks.  All  sta-
istical  analyses  were  performed  using  Epi-Info  3.5.1  (Epi
nfoTM,  GA,  USA)  and  Microsoft  Excel  2007  (Microsoft®, WA,
SA).
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Table  1  Demographic  and  clinical  characteristics  of  hos-
pitalized  intussusception  cases.  State  of  São  Paulo,  Brazil,
2001--2008  (n  =  331).
Intussusception  cases
Male  sex,  n  (%)  197  (59.5)
Age --  (weeks)
Median  26
Range 1--52
Duration  of  symptoms  before  hospitalization  (days)
Median  1
Range 0--7
Sign  and  symptoms,  n/total  number  (%)a
Vomiting  288/322  (89.4)
Bloody  stoolb 191/253  (75.5)
Abdominal  distention 183/255  (71.8)
Hematocheziac 182/293  (62.1)
Blood  detected  on  rectal  exam 113/202  (55.9)
Pallor 123/234  (52.6)
Fever  135/307  (44.0)
Abdominal  mass 105/273  (38.5)
Lethargy  69/223  (30.9)
Rectal  mass 30/209  (14.4)
Method  of  diagnosis  (%)
Ultrasound  146  (44.1)
Contrast  enema  71  (21.5)
Surgery  113  (34.1)
Necropsy  1  (0.3)
Deﬁnitive  treatment  (%)
Air  or  contrast  enema  26  (7.9)
Abdominal  surgery  305  (92.1)
Without  bowel  resection  159  (52.1)
With bowel  resection  97  (31.8)
Unknown  49  (16.1)
Duration  of  hospitalization  --  days
Median  5
Range 0--76
Death  (%)  13/331  (3.9)
a Missing data not included.
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mb Bloody stool: stool mixed with blood (‘‘currant jelly’’).
c Hematochezia: passage of fresh blood through the anus.
thics
he  study  was  approved  by  the  Ethics  Committee  of  Irman-
ade  da  Santa  Casa  de  Misericórdia  de  São  Paulo,  registration
o.  38053.
esults
linical  and  demographic  characteristics  of  casesetween  2001  and  2008,  a  total  of  331  intussusception  cases
ere  identiﬁed  in  São  Paulo  state  (Fig.  1).  Intussusception
ases  were  more  likely  to  be  male  (59.5%)  and  had  a  median
ge  of  26  weeks  (Table  1),  with  peak  incidence  among  those
t
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8--24  weeks  of  age  (Fig.  2).  Only  9.1%  of  the  intussusception
vents  occurred  among  children  <15  weeks  of  age,  when  the
nitial  dose  of  rotavirus  vaccines  is  typically  administered  in
razil,  whereas  36.6%  occurred  among  those  15--24  weeks
f  age,  when  the  second  dose  of  rotavirus  vaccine  is  typi-
ally  administered,  and  54.4%  among  those  25--52  weeks  of
ge.  Intussusception  events  occurred  year-round,  without
vidence  of  a  seasonal  peak  (data  not  shown).
The  most  frequently  observed  signs  or  symptoms  (Table  1)
ncluded  vomiting  (89.4%),  bloody  stool  (75.5%),  and  abdom-
nal  distention  (71.8%).  Mean  duration  of  symptoms  before
resenting  for  medical  care  was  roughly  one  day.  Diagnosis
f  intussusception  was  made  by  ultrasonography,  contrast
nema,  and  surgery  in  44.1%,  21.5%,  and  34.1%  of  the
ase-patients,  respectively.  A  majority  (92.1%)  of  the  case-
atients  were  surgically  treated  for  intussusception,  with
t  least  31.8%  of  those  who  underwent  surgery  requiring
owel  resection.  Among  the  331  case-patients  hospitalized
or  intussusception  during  the  study  period,  13  (3.9%)  died.
mong  those  surviving,  the  mean  duration  of  hospitalization
as  approximately  ﬁve  days  (range:  0--76  days).
emporal  distribution  of  cases
mong  the  331  case-patients,  246  (74.3%)  were  from  21
ospitals  that  identiﬁed  and  reported  intussusception  dur-
ng  the  entire  surveillance  period,  2001--2008.  The  overall
emographic  and  clinical  characteristics  of  cases  from  these
1  hospitals  were  similar  to  those  of  cases  from  hospitals
hat  only  reported  cases  for  part  of  the  surveillance  period
data  not  shown).  When  restricting  the  analysis  to  cases
t  the  21  hospitals  with  stable  reporting  during  the  entire
001--2008  surveillance  period,  no  increase  was  observed  in
he  number  of  reported  intussusception  events  during  the
urveillance  period  after  vaccine  introduction.  The  observed
umber  of  intussusception  events  during  2007  (n  =  26)  and
008  (n  =  19)  was  somewhat  lower  than  the  average  annual
umber  of  intussusception  cases  (n  =  32  cases  per  year,  range
4--42  cases  per  year)  during  2001--2005  (Fig.  3).
iscussion
fforts  to  build  capacity  for  intussusception  monitoring  by
he  Division  of  Immunization  of  the  State  of  São  Paulo  iden-
iﬁed  several  important  lessons  for  future  rotavirus  vaccine
afety  monitoring  efforts  in  Brazil.  First,  the  age  distribution
f  intussusception  in  São  Paulo  is  similar  to  that  in  other
egions  of  the  world,  with  <10%  of  cases  occurring  among
hose  <15  weeks  of  age.15--17 At  this  age,  the  ﬁrst  dose  of
otavirus  vaccine  --  the  dose  with  the  highest  potential  risk
f  intussusception  --  is  typically  administered.  This  ﬁnding
ndicates  that  it  would  be  necessary  to  expand  surveil-
ance  to  a large  number  of  hospitals  in  order  to  identify
nough  cases  to  assess  risk  of  intussusception  after  the  initial
ose  of  rotavirus  vaccination.  Identifying  a  four-  to  ﬁve-fold
ncrease  in  risk  of  intussusception  relative  to  background
ight  not  be  possible  when  assessing  trends  of  intussuscep-ion  among  all  infants  under  one  year  of  age  who  typically
ave  background  rates  of  ∼40--50  per  100,000.18 Second,
urgery  is  the  most  common  treatment  of  intussusception
n  Brazil,  compared  with  more  developed  settings  where
Hospital-based  surveillance  of  intussusception  185
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Figure  2  Age  distribution  of  infants  with  intussusceptions  by  week  of  age  from  58  hospitals  in  São  Paulo  State,  2001--2008  (n  =  331).
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Figure  3  Trends  in  yearly  intussusception  hospitalizations
among  infants  aged  <12  months  between  2001  and  2008.  Data
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nnon-surgical  treatment  with  air/contrast  enema  is  used
more  often.19--21 This  ﬁnding  has  implications  for  resource-
poor  settings,  in  that  networking  with  surgeons  and  hospitals
with  surgical  centers  could  enhance  surveillance  for  intus-
susception  after  the  introduction  of  vaccine.  Third,  while
cautious  interpretation  is  warranted,  this  study  did  not
observe  a  substantial  increase  in  the  number  of  intussus-
ception  cases  during  the  post-vaccine  introduction  period,
when  some  85%  of  the  infants  had  received  vaccination  in
Brazil.
Brazil  was  one  of  the  early  adopters  of  rotavirus  vaccine,
and  has  documented  large  reductions  in  hospitalizations
and  deaths  related  to  diarrhea  among  children  under  ﬁve
years  age  since  the  introduction  of  rotavirus  vaccines.14
While  clinical  trials  for  rotavirus  vaccines  have  not  identi-
ﬁed  a  vaccine-associated  increased  risk  of  intussusception,
large  post-licensure  evaluations  in  Mexico  and  Australia  have
found  a  low  risk  after  the  ﬁrst  dose  of  both  rotavirus  vac-
cines,  amounting  to  roughly  one  to  four  excess  cases  of
intussusception  for  every  100,000  vaccinated  children.7--9
While  a  cautious  interpretation  is  warranted,  since  the
present  surveillance  was  not  intended  to  quantify  risk  of
intussusception  associated  with  RV1,  it  is  reassuring  that
there  was  no  large  increase  in  intussusception  cases  at  a
population  level  following  vaccine  introduction  in  the  state
of  São  Paulo,  Brazil.
Trend  analysis  cannot  exclude  a  risk  of  similar  magnitude
to  that  seen  in  Mexico  and  Australia  after  the  initial  dose,
particularly  because  background  rates  of  intussusception
are  very  low  (∼10--20  per  100,000  infant  years  during  6--12
weeks  of  age  when  the  ﬁrst  dose  is  administered  in  Brazil).3,9
Assessing  trends  in  narrow  age  windows  might  be  useful,  but
sample  size  is  typically  insufﬁcient  for  conﬁdently  excluding
risk,  even  with  national  datasets  from  countries  with  large
birth  cohorts,  such  as  the  United  States.3
Analytic  epidemiologic  studies,  such  as  those  employ-
ing  the  case-series  or  the  case--control  method,  would  be
t
r
t
cre from  21  sentinel  hospitals  of  the  hospital-based  intussus-
eption  surveillance  of  São  Paulo  State,  Brazil  (n  =  246).
ecessary  for  assessing  a  magnitude  of  risk  of  one  to  two
xcess  adverse  events  per  100,000  vaccinated  children.
urveillance  platforms  similar  to  that  established  by  the
tate  of  São  Paulo  are  the  backbone  for  such  epidemio-
ogic  studies,  provided  that  intussusception  case-ﬁnding  is
ctive  and  independent  of  the  vaccination  status.  Indeed,
everal  of  these  hospitals  from  São  Paulo  enhanced  and
ontinued  surveillance  as  part  of  a  nationwide  study  in
razil  that  assessed  risk  of  intussusception  after  RV1  using
elf-controlled  case-series  and  case--control  design.  In  that
ationwide  study,  no  risk  of  intussusception  was  found  after
he  ﬁrst  dose  of  rotavirus  vaccine  in  Brazil,  but  a  low-level
isk  was  detected  after  the  second  dose.9 Initiating  this
ype  of  active  hospital  based  surveillance  for  speciﬁc  out-
omes  such  as  intussusception  would  be  valuable  for  safety
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186  
onitoring  in  other  settings  without  any  existing  national
afety  monitoring  platforms,  particularly  for  building  capac-
ty  for  safety  monitoring  and  for  obtaining  established
latforms  that  can  be  utilized  for  specialized  studies  for
ssessing  risk  as  new  safety  concerns  arise.
In  the  present  cohort,  90%  of  the  intussusception  case-
atients  required  surgery.  This  is  comparable  to  treatment
tandards  in  resource  poor  settings,  while  in  industrial-
zed  countries  only  10--50%  of  patients  require  surgical
reatment.15,19--21 The  reasons  for  the  high  rates  of  surgi-
al  treatment  among  cases  remain  a  subject  for  further
nvestigation.  Delays  in  presentation  and  treatment  may
lso  explain  the  higher  in-hospital  mortality  of  4--5%  in
ome  regions  of  Brazil9 and  ∼12--13%  reported  from  Africa,15
ompared  with  1%  in  Mexico9 and  <1%  in  industrialized
ountries.19--21 Improving  diagnosis  and  early  intervention
ith  non-invasive  reduction  techniques  have  the  potential
o  reduce  morbidity  and  mortality  in  Brazil.  Further  stud-
es  identifying  risk-factors  for  severe  outcomes  related  to
ntussusception  in  Brazil  are  warranted.
This  evaluation  has  several  limitations.  First,  this  study
onsidered  sentinel  services.  The  reported  cases  do  not  rep-
esent  all  intussusception  cases  of  São  Paulo  state  during
he  studied  period.  The  selected  services  have  30%  of  pedi-
trics  beds  of  the  State  of  São  Paulo’s  public  health  system,
hich  covers  ∼60%  the  population.  Without  a  precise  popu-
ation  denominator,  it  is  not  possible  to  calculate  incidences.
esults  in  absolute  numbers  can  be  inﬂuenced  by  popu-
ation  changes,  such  as  decrease  in  birth  rate  over  time.
econd,  using  different  surveillance  methods  before  and
fter  the  introduction  of  vaccine  limits  the  ability  to  conﬁ-
ently  compare  the  rate  of  events  between  the  two  periods,
articularly  because  of  differences  in  methods  of  ascertain-
ng  cases.  These  results  alone  cannot  be  used  to  refute  a
asual  association  between  rotavirus  vaccination  and  intus-
usception,  and  cannot  be  directly  compared  with  data  from
ost-licensure  monitoring  in  Mexico  and  Australia.7,8 Third,
accination  history  of  cases  was  not  available.  Moreover,  the
ompleteness  and  accuracy  of  data  describing  the  clinical
resentation  and  management  of  intussusceptions  reﬂects
ecording  completeness  in  medical  records.  Fourth,  intus-
usception  is  a  rare  event,  especially  among  infants  aged  <3
onths;  relatively  small  changes  in  absolute  numbers  in  nar-
ower  age  ranges,  such  as  infants  aged  6--14  weeks,  could
esult  an  increase  or  decrease  in  trend  by  chance  alone.
ast,  hospital  based  surveillance  may  not  be  representative
f  all  intussusception  events,  particularly  in  resource  poor
ettings  where  access  to  pediatric  diagnostic  facilities  and
reatment  is  limited.
Since  2006,  rotavirus  vaccines  have  been  introduced
n  over  30  countries  worldwide.22 While  the  beneﬁts  of
otavirus  vaccination  in  terms  of  reducing  severe  and  fatal
iarrhea  have  far  outweighed  the  low  risk  of  intussuscep-
ion,  the  ongoing  monitoring  of  intussusception  after  the
ntroduction  of  vaccine  is  important  for  ensuring  vaccine
afety  and  maintaining  public  trust  in  the  rotavirus  vaccine
rogram.  The  present  experience,  establishing  intussuscep-
ion  surveillance  for  monitoring  post  licensure  rotavirus
accine  safety  in  São  Paulo,  should  provide  valuable  infor-
ation  for  other  similar  countries  that  are  introducing
otavirus  vaccine  and  do  not  have  existing  safety  monitoring
ystems.
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